Detecting Cytokeratin 19 mRNA in the Peripheral Blood Cells of Cervical Cancer Patients and Its Clinical–Pathological Correlation

Yuan, Chiou‐Chung; Wang, Peng-Hui; Ng, Heung‐Tat; Li, Ywan-Feng; Huang, Tze-Sing; Chen, Ching-Yi; Tsai, Li-Ping; Shyong, Wen-Yuann

doi:10.1006/gyno.2002.6587

Cited by 14 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the results diverge considerably and the clinical significance is still unclear. [17][18][19][20][21][22][23][24] The aim of this study was to evaluate the sensitivity and specificity of molecular markers for the detection of tumour cells in SLN at the RNArather than at the protein-level. PCR-based assays are extremely sensitive and are less vulnerable to intranodal tumour cell distribution when compared to IHC.…”

mentioning

confidence: 99%

HPV16‐E6 mRNA is superior to cytokeratin 19 mRNA as a molecular marker for the detection of disseminated tumour cells in sentinel lymph nodes of patients with cervical cancer by quantitative reverse‐transcription PCR

Häfner

Gajda

Altgassen

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

About 10-15% of patients with cervical cancer suffer from recurrence despite histologically negative lymph nodes (pN0). Occult micrometastases or small tumour cell clusters may contribute to disease outcome. The aim of this study was to compare at the RNA level 2 known tumour-associated genes, HPV16-E6 and cytokeratin 19 (CK19), as molecular markers for the detection of disseminated tumour cells. Real-time reverse transcription PCR technology was used to quantify gene expression in histologically positive and negative sentinel lymph nodes (SLN) from 70 patients with cervical cancer. Lymph nodes from noncancer patients were used as controls. Calculated copy numbers were normalised to the geometric average of the most stable housekeeping genes. We observed a good correlation (R 5 0.915) between the expression of both markers in SLN with histologically confirmed metastases. However, marker gene expression differed considerably in histologically negative nodes: CK19 transcripts were detected in 90 of 112 SLN (80.4%), whereas only 38 nodes (33.9%) were positive for HPV16 E6 mRNA. In particular, 62 of 74 SLN, which were negative by histology, and HPV16 E6 mRNA expressed CK19 mRNA. Moreover, 8 of 10 lymph nodes from noncancer patients expressed CK19 mRNA. Systematic errors due to RNA degradation or incomplete cDNA could be ruled out. It is concluded that HPV16 E6 mRNA is more specific and more sensitive for the detection of tumour cells in SLN than CK19 mRNA. The specificity of CK19 is limited because of low level expression in uninvolved pelvic lymph nodes. ' 2007 Wiley-Liss, Inc.Key words: cervical cancer; disseminated tumour cells; molecular markers; HPV16-E16; cytokeratin 19; quantitative RT-PCR Cervical cancer is the second most common cancer among women world wide, accounting for 493,000 new cases in 2002. 1 The incidence rates vary considerably between different geographic regions, which reflect in part the lack of screening programs in developing countries. Despite the advancement in early diagnosis, improved surgical techniques and adjuvant therapies, approximately 40% of cervical carcinoma patients in countries with a high standard of health care die from the disease. 1 The majority of these deaths is due to metastases. 2 Different parameters such as lymph node metastases, tumour grade, lymph-vascular space involvement (LVSI) and surgical margins are prognostic factors for cervical cancer, with lymph node status as the most important one. 3,4 Patients with histologically uninvolved lymph nodes (pN0) have a better prognosis than women with histologically confirmed lymph node metastasis (pN1) showing 5 year survival rates of 88-93% and 40-63%, respectively. 5-7 Nevertheless 15% of FIGO stage IB patients with pathologically staged negative lymph nodes (pN0) suffer from recurrence. 8 The significance of micrometastases as a predictive factor for recurrent disease is the focus of several recent and ongoing studies. Extensive serial sectioning of lymph nodes that were judged to be free of disease by routine diagnos...

show abstract

mentioning

confidence: 99%

HPV16‐E6 mRNA is superior to cytokeratin 19 mRNA as a molecular marker for the detection of disseminated tumour cells in sentinel lymph nodes of patients with cervical cancer by quantitative reverse‐transcription PCR

Häfner

Gajda

Altgassen

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…CTCs in patients with cervical cancer were already found in 1969, even in patients with 'carcinoma in situ' (181). This was confirmed in 2002, as the presence of CTCs in early stage cervical cancer samples was analysed by real-time PCR using CK19 as marker gene (182). It was concluded, that tumour cell dissemination is one of the early steps in tumour progression.…”

Section: Recent Developments For Ctc Detection In Ovarian Cancermentioning

confidence: 81%

Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review)

et al. 2016

View full text Add to dashboard Cite

“…So CK19 probably possesses higher expression in pleural effusions resulted from these tumors. CK19 mRNA was frequently used as a marker in the detection of circulating tumor cells of epithelial origin and sensitivity of this assay was 1 CK19-mRNA-positive cell per 10 6 mononuclear cells (Yuan et al, 2002). But CK19 mRNA has rarely been investigated in pleural effusions.…”

Section: Comparison Of Positive Rate Of Ck19 Mrna and Ck19 In Pleuralmentioning

confidence: 99%

“…Sequential quantification of CK19 mRNA levels in blood may potentially indicate colorectal cancer patients response to treatment and help identify patients at high risk for metastasis (Wong et al, 2001). Yuan et al(2002) revealed the presence of circulating CK19-expressing cancer cells in the blood of patients with untreated early-stage cervical carcinomas. Lockett et al(1998) had developed keratin-19, c-myc, prolactin inducible protein (PIP) RT-PCR based method to identify axillary lymph node metastases in patients with breast cancer and thought it appeared to be a readily available and highly sensitive method for detecting breast cancer micrometastases.…”

Section: Introductionmentioning

confidence: 99%

The diagnostic significance of the detection of cytokeratin 19 mRNA by quantitative RT-PCR in benign and malignant pleural effusions

Chen

Shen

et al. 2004

J. Zheijang Univ.-Sci.

View full text Add to dashboard Cite

Abstract:Objective: To evaluate the diagnostic significance of detecting cytokeratin 19 (CK19) mRNA by quantitative reverse transcription polymerase chain reaction (RT-PCR) in benign and malignant pleural effusions. Methods: CK19 mRNA was examined by quantitative RT-PCR and CK19 was detected by Enzyme-linked immunoadsorbent assay (ELISA) in 32 patients with malignant pleural effusions and 35 patients with benign pleural effusions. Results: On the threshold of 200 copies/µl, the positive rate of CK19 mRNA in patients with malignant pleural effusions was 62.5%. The positive rates of CK19 mRNA and CK19 in the malignant pleural effusions were significantly higher than those in the benign group (P<0.01). Furthermore, the positive rate of CK19 mRNA was higher than that of CK19 in the malignant group (P<0.05). Conclusion: Detection of CK19 mRNA can be a promising diagnostic marker in differential diagnosis of benign and malignant pleural effusions.

show abstract

Detecting Cytokeratin 19 mRNA in the Peripheral Blood Cells of Cervical Cancer Patients and Its Clinical–Pathological Correlation

Cited by 14 publications

References 17 publications

HPV16‐E6 mRNA is superior to cytokeratin 19 mRNA as a molecular marker for the detection of disseminated tumour cells in sentinel lymph nodes of patients with cervical cancer by quantitative reverse‐transcription PCR

HPV16‐E6 mRNA is superior to cytokeratin 19 mRNA as a molecular marker for the detection of disseminated tumour cells in sentinel lymph nodes of patients with cervical cancer by quantitative reverse‐transcription PCR

Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review)

The diagnostic significance of the detection of cytokeratin 19 mRNA by quantitative RT-PCR in benign and malignant pleural effusions

Contact Info

Product

Resources

About